Abstract
The present report concerns HPLC method development for chemical samples of a new antiarrhythmic drug 2-methyl-5-phenyl-5-[2-[2-N, N-bis (1-methylethyl amino] ethyl]-1,3 diazabicyclo [4.4.0] octen-4-one (MPMED). Selectivity optimization for MPMED and several synthetic process intermediates with reversed-phase HPLC conditions is described. Also, the use of electrochemical and UV absorption detection for MPMED samples has been evaluated. The developed method has been validated for generation of assay data for chemical lots of MPMED.

This publication has 9 references indexed in Scilit: